Kanan Nuriyev

Kanan Nuriyev

Auto-generated profile, based on publicly available information

Kanan Nuriyev

Division of Gastroenterohepatology Department of Internal Medicine Istanbul Faculty of Medicine Istanbul University Istanbul Türkiye

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2025 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
FKFatih Kemik
Fatih Kemik
GCGozde Ceylan
Gozde Ceylan
AAA. Fatih Aydın
A. Fatih Aydın
BÇBilger Çavuş
Bilger Çavuş
AOAsli Ormeci
Asli Ormeci
KDKadir Demir
Kadir Demir
Background/Aims: Functional dyspepsia (FD) is diagnosed in the absence of an identifiable organic cause. Pancreatic enzyme insuf ficiency (PEI) remains an underrecognized condition in these patients. This study aimed to investigate the prevalence of PEI among FD patients unresponsive to standard therapy and to evaluate its clinical and biochemical characteristics. Materials and Methods: A total of 154 patients diagnosed with FD were followed, among which 66 patients who did not respond to at least 4 weeks of standard treatment, including acid-reducing therapies, prokinetics, and antidepressants, were evaluated. Additionally, 34 healthy volunteers were included as a control group. Organic pathologies were excluded in all 66 patients with FD resistant to stan dard treatment using endoscopy, endoscopic biopsy, and imaging methods. Fecal elastase-1 (FE-1) enzyme levels were measured to determine the prevalence of PEI in both groups. Results: Pancreatic enzyme insufficiency was detected in 5 (7.57%) of the 66 treatment-resistant FD patients, while none of the con trols had PEI. The prevalence of PEI was significantly higher in diabetic patients than in non-diabetic patients within the study group (P = .037). Patients with diarrhea, sticky stools, and frequent foul-smelling stools exhibited a higher prevalence of PEI (P = .022, P = .001, and P = .004, respectively). In the study group, PEI patients had lower serum calcium, phosphorus, and magnesium levels than the control group (P = .018, P = .011, and P = .001, respectively). Conclusion: Pancreatic enzyme insufficiency was identified in 7.57% of patients resistant to standard treatment. In patients resistant to standard therapy for at least 4 weeks, the presence of symptoms such as diarrhea, sticky stools, and foul-smelling stools, along with diabetes mellitus and low serum calcium, phosphorus, and magnesium levels, may warrant consideration of PEI as a potential underlying condition. Cite this article as: Kemik F, Ceylan G, Aydin AF, et al. The role of pancreatic enzyme insufficiency in the etiology of functional dyspepsia resistant to standard treatment. Turk J Gastroenterol. 2025;36(7):467-473.

31 March 2026 in MedEpicent: Journal of Medical Education and Clinical Research
Verified
Journal Article
Closed access
SVSamaya Valizada
Samaya Valizada
KNKanan Nuriyev
Kanan Nuriyev
Autoimmune pancreatitis ( AIP) is a rare type of chronic pancreatitis characterized by immune-mediated inflammation of the pancreas.It is often misdiagnosed due to non-specific symptoms such as abdominal pain, congestion , jaundice and radiographic findings that mimic pancreatic malignancy.Without appropriate treatment ,AIP can lead to endocrine and exocrine pancreatic insufficiency,biliary complications , and irreversible fibrosis(1).In this article, we aimed to increase awareness of the clinical approach to IgG4 –unrelated autoimmune pancreatitis that mimics pancreatic malignancy

30 May 2026 in Journal of Periodontology
Verified
Journal Article
Closed access
HBHanne Bulut
Hanne Bulut
EÖElif Öğüt
Elif Öğüt
KNKanan Nuriyev
Kanan Nuriyev
FBFatih Beşışık
Fatih Beşışık
BKBurcu Karaduman
Burcu Karaduman

2 July 2025 in Transplant Infectious Disease
Verified
Journal Article
Closed access
EBErdem Bektas
Erdem Bektas
AYAysenur Yilmaz
Aysenur Yilmaz
CKCevat Ilteris Kikili
Cevat Ilteris Kikili
KNKanan Nuriyev
Kanan Nuriyev
ZIZulal Istemihan
Zulal Istemihan
SKSabahattin Kaymakoglu
Sabahattin Kaymakoglu

1 March 2025 in Annals of Internal Medicine: Clinical Cases
Verified
Journal Article
Closed access
ABAli Emre Bardak
Ali Emre Bardak
NSNaci Senkal
Naci Senkal
KNKanan Nuriyev
Kanan Nuriyev
AMAlpay Medetalibeyoglu
Alpay Medetalibeyoglu

1 January 2025 in International Journal of Hepatology
Verified
Journal Article
Open access
EBErdem Bektas
Erdem Bektas
AYAysenur Yilmaz
Aysenur Yilmaz
CKCevat Ilteris Kikili
Cevat Ilteris Kikili
KNKanan Nuriyev
Kanan Nuriyev
ZIZulal Istemihan
Zulal Istemihan
SKSabahattin Kaymakoglu
Sabahattin Kaymakoglu
Hepatitis B virus (HBV) infection is an important health concern worldwide. HBV infection can lead to acute hepatitis, cirrhosis, hepatocellular carcinoma, liver failure, and death. Nucleos(t)ide analogs (NAs) form the core of the HBV treatment. The safety and efficacy of NAs in long‐term follow‐up are still critical issues. We enrolled 225 consecutive patients with at least 12 months of longitudinal follow‐up using tenofovir alafenamide (TAF), including 39 antiviral naïve and 186 antiviral experienced patients. In the treatment‐experienced group, the main reasons for switching from other NAs to TAF were renal dysfunction and osteoporosis. Renal outcome, lipid profile, virological response, and ALT normalization under the TAF treatment were evaluated. Age > 60 years, liver transplant recipients, and patients with decompensated cirrhosis were evaluated separately, as well as the total cohort. Phosphorus levels increased especially in hypophosphatemic individuals, eGFR levels also increased slightly but statistically significantly, and the remarkable improvement in eGFR stages was observed in the eGFR < 60 mL/min/1.73 m 2 group. A minimal increase in LDL‐c levels occurred after TAF treatment, which did not reach statistical significance. Total cholesterol and HDL‐c levels increased significantly, while triglyceride levels remained unchanged. In the total cohort, HBV‐DNA was strongly suppressed in either treatment‐naïve or experienced patients. ALT and AST levels decreased with the TAF treatment, but ALT normalization rate did not change significantly. No serious adverse events associated with TAF occurred, and discontinuation was not required in the total cohort. Our findings support that TAF treatment is well‐tolerated and effective in patients with chronic HBV infection.